Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Skip to Content

Clinical Trial Details

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Objective

NSABP B-55 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy NCT#02032823

IRB Protocol Number
NSABP B-55

Clinical Trial Categories

  • Breast Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6031